|Dr. Fredric N. Eshelman Pharm.D.||Exec. Chairman||78.29k||N/A||68|
|Dr. Clive A. Meanwell M.D., Ph.D.||CEO & Director||1.75M||824.05k||59|
|Mr. Stuart Anthony Kingsley MBA||Pres and Chief Operating Officer||723.78k||N/A||53|
|Mr. William B. O'Connor||Chief Financial Officer||863.37k||N/A||58|
|Mr. Stephen M. Rodin J.D.||Exec. VP, Gen. Counsel and Sec.||798.42k||N/A||41|
The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms. The companys approved products include Adenosine, Amiodarone, Esmolol, and Milrinone for acute cardiovascular; Azithromycin and Clindamycin for serious infectious disease; and Haloperidol, Midazolam, Ondansetron, and Rocuronium for surgery and perioperative treatment. Its research and development stage products comprise Carbavance, an antibiotic agent that has completed Phase III development stage for the treatment of hospitalized patients with serious gram-negative bacterial infections; Inclisiran, a synthesis inhibitor for the potential treatment of hypercholesterolemia; and MDCO-700, an intravenous anesthetic agent developed for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures. The Medicines Company has a collaboration agreement with Alnylam Pharmaceuticals, Inc.; SciClone Pharmaceuticals; and Symbio Pharmaceuticals Limited. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.
The Medicines Company’s ISS Governance QualityScore as of December 1, 2017 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 4; Compensation: 7.